HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+lymphoma
Por:
Caballero, AC, Ujaldón-Miró, C, Pujol-Fernández, P, Montserrat-Torres, R, Guardiola-Perello, M, Escudero-López, E, Garcia-Cadenas, I, Esquirol, A, Martino, R, Jara-Bustamante, P, Ezquerra, P, Soria, JM, Iranzo, E, Moreno-Martinez, ME, Riba, M, Sierra, J, Alvarez-Fernández, C, Escribà-Garcia, L and Briones, J
Publicada:
17 abr 2025
Ahead of Print:
1 abr 2025
Resumen:
CD30-directed chimeric antigen receptor T-cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the nonsoluble part of CD30, and the manufacturing process includes a modulation of ex vivo T-cell activation, as well as the addition of interleukin-21 (IL-21) to IL-7 and IL-15 to promote stemness of T cells. We translated HSP-CAR30 to a phase 1 clinical trial of 10 patients with relapsed/refractory classic Hodgkin lymphoma (HL) or CD30+ T-cell non-Hodgkin lymphoma. HSP-CAR30 was mainly composed of memory stem-like (TSCM-like) and central memory (TCM) CAR30+ T cells (87.5% +/- 5%). No dose-limiting toxicities were detected. Six patients had grade 1 cytokine release syndrome, and no patient developed neurotoxicity. The overall response rate was 100%, and 5 of 8 patients with HL achieved complete remission (CR). An additional patient with HL achieved CR after a second HSPCAR30 infusion. Remarkably, 60% of patients have ongoing CR after a mean follow-up of 34 months. CAR30+ T cells at expansion peak had a predominance of TSCM and TCM cells, and CAR30+ T cells remained detectable in 3 of 5 evaluable patients at least 12 months after infusion. Our study shows that selection of the epitope targeting CD30 and ex vivo preservation of less-differentiated memory T cells may enhance the efficacy of CART30 in patients with refractory HL.
Filiaciones:
Caballero, AC:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ujaldón-Miró, C:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Pujol-Fernández, P:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Montserrat-Torres, R:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Guardiola-Perello, M:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Escudero-López, E:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Garcia-Cadenas, I:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Esquirol, A:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Martino, R:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Ezquerra, P:
Res Inst St Pau Hosp, Unit Genom Complex Dis, Barcelona, Spain
Inst Salud Carlos III, Ctr Biomed Network Res Rare Dis, Madrid, Spain
Inst Invest Biomed St Pau, Barcelona, Spain
Soria, JM:
Res Inst St Pau Hosp, Unit Genom Complex Dis, Barcelona, Spain
Inst Salud Carlos III, Ctr Biomed Network Res Rare Dis, Madrid, Spain
Inst Invest Biomed St Pau, Barcelona, Spain
Iranzo, E:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Moreno-Martinez, ME:
Inst Invest Biomed St Pau, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Pharm Serv, Barcelona, Spain
Riba, M:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Barcelona, Spain
Hosp Santa Creu & Sant Pau, Pharm Serv, Barcelona, Spain
Sierra, J:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Barcelona, Spain
Alvarez-Fernández, C:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Escribà-Garcia, L:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
Briones, J:
Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain
Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain
Josep Carreras Leukemia Res Inst, Barcelona, Spain
|